Steven Wade Andrews

USPTO Granted Patents = 97 (Patent Applications = 15)

CIPO Patents = 12 (Patent Applications = 8)

EPO Patents = 23 (Patent Applications = 27)

Average Co-Inventor Count = 5.2

ph-index = 22

Forward Citations = 1,885(Granted Patents)

Forward Citations (Not Self Cited) = 1,369(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Rancho Santa Marguerita, CA (US) (1997 - 2002)
Rancho Santa Margarita, CA (US) (2001 - 2002)
Irvine, CA (US) (1994 - 2011)
Langmont, CO (US) (2012)
Longmont, CO (US) (2003 - 2024)
Boulder, CO (US) (2013 - 2024)

Company Filing History:

Eli Lilly and Company

where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...

97 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

2. 11970485 - RET kinase inhibitors (2024-04-30),

3. 11964968 - Compounds useful for inhibiting RET kinase (2024-04-23),

4. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (2023-12-26),

5. 11697647 - RET kinase inhibitors (2023-07-11),

6. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

7. 11613533 - Compounds useful for inhibiting RET kinase (2023-03-28),

8. 11267818 - Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds (2022-03-08),

9. 11214571 - Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof (2022-01-04),

10. 11168090 - Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors (2021-11-09),

11. 10966985 - Macrocyclic compounds as ROS1 kinase inhibitors (2021-04-06),

12. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),

13. 10907215 - Point mutations in TRK inhibitor-resistant cancer and methods relating to the same (2021-02-02),

14. 10889589 - Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain (2021-01-12),

15. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),

Certainly! Here is an article about inventor Steven Wade Andrews:

Title: Unveiling the Ingenious Mind of Steven Wade Andrews

Introduction:

In the realm of innovation, Steven Wade Andrews shines as a prolific inventor based in Boulder, CO (US). With an impressive portfolio of 94 patents, his contributions have significantly impacted the field of pharmaceuticals and healthcare.

Latest Patents:

Among his latest patents is the groundbreaking work on "Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors." These compounds, along with others like "RET kinase inhibitors," showcase Steven's expertise in developing novel pharmaceutical solutions for treating various diseases and disorders.

Career Highlights:

Steven Wade Andrews has lent his inventive prowess to renowned companies such as Array Biopharma Inc. and Allergan, Inc. His collaborations within these organizations have led to the successful development and commercialization of innovative healthcare products.

Collaborations:

Throughout his career, Steven has collaborated with esteemed professionals in the industry, including coworkers like Yutong Jiang and Julia Haas. Together, they have synergized their skills to drive forward cutting-edge research and product development initiatives.

Conclusion:

In conclusion, Steven Wade Andrews stands as a trailblazing inventor whose relentless pursuit of innovation has culminated in numerous patents that have the potential to transform the landscape of healthcare. His contributions serve as a testament to the power of creativity and dedication in advancing scientific knowledge and medical treatments.

This text is generated by artificial intelligence and may not be accurate.